Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

Tofacitinib is an oral Janus kinase inhibitor. An integrated analysis was conducted to evaluate dosage optimality for tofacitinib in patients with moderate‐to‐severe plaque psoriasis and the impact of body weight on optimality in this patient population. Data were pooled from one phase IIb trial (2,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CPT Pharmacometrics Syst Pharmacol
Main Authors: Hutmacher, MM, Papp, K, Krishnaswami, S, Ito, K, Tan, H, Wolk, R, Valdez, H, Mebus, C, Rottinghaus, ST, Gupta, P
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5445230/
https://ncbi.nlm.nih.gov/pubmed/28317328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12182
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados